162 related articles for article (PubMed ID: 38430481)
1. Development of cytomegalovirus resistant to maribavir: real world, real problem?
Kleiboeker HL; Prom A; Paplaczyk K
Transpl Infect Dis; 2024 Apr; 26(2):e14259. PubMed ID: 38430481
[No Abstract] [Full Text] [Related]
2. Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients.
Chou S; Alain S; Cervera C; Chemaly RF; Kotton CN; Lundgren J; Papanicolaou GA; Pereira MR; Wu JJ; Murray RA; Buss NE; Fournier M
J Infect Dis; 2024 Feb; 229(2):413-421. PubMed ID: 37506264
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of maribavir versus conventional antiviral therapies for post-transplant refractory cytomegalovirus infection with or without genotypic resistance: A US perspective.
Schultz BG; Kotton CN; Jutlla G; Ressa R; de Lacey T; Chowdhury E; Bo T; Fenu E; Gelone DK; Poirrier JE; Amorosi SL
J Med Virol; 2024 Apr; 96(4):e29609. PubMed ID: 38647051
[TBL] [Abstract][Full Text] [Related]
4. Use of Maribavir for Multidrug Resistant Cytomegaloviremia in a Pediatric Oncology Patient.
Fisher JE; Mulieri K; Finch E; Ericson JE
J Pediatr Hematol Oncol; 2024 Apr; 46(3):e244-e247. PubMed ID: 38447094
[TBL] [Abstract][Full Text] [Related]
5. [Not Available].
Loft JA; Riis PT; Schultz NA; Bjerrum S; Schønning K; Pedersen CR; Krohn PS; Nielsen SD
Ugeskr Laeger; 2024 Apr; 186(15):. PubMed ID: 38708697
[TBL] [Abstract][Full Text] [Related]
6. A Novel Case of CMV Resistance to Valganciclovir and Maribavir in a Renal Transplant Patient.
Pearce H; Montgomery EK; Sheerin N; Ellam H
Transpl Int; 2024; 37():11985. PubMed ID: 38314399
[No Abstract] [Full Text] [Related]
7. Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants.
Chou S; Watanabe J
Antiviral Res; 2024 Feb; 222():105792. PubMed ID: 38163624
[TBL] [Abstract][Full Text] [Related]
8. Maribavir failure in refractory cytomegalovirus infection in a lung transplant patient on extracorporeal membrane oxygenation.
Kroll C; Non L; Ince D
Transpl Infect Dis; 2024 Jun; 26(3):e14275. PubMed ID: 38584587
[No Abstract] [Full Text] [Related]
9. Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial.
Avery RK; Alain S; Alexander BD; Blumberg EA; Chemaly RF; Cordonnier C; Duarte RF; Florescu DF; Kamar N; Kumar D; Maertens J; Marty FM; Papanicolaou GA; Silveira FP; Witzke O; Wu J; Sundberg AK; Fournier M;
Clin Infect Dis; 2022 Sep; 75(4):690-701. PubMed ID: 34864943
[TBL] [Abstract][Full Text] [Related]
10. EFFICACY OF MARIBAVIR IN VALGANCICLOVIR-RESISTANT CYTOMEGALOVIRUS RETINITIS.
Tsui JC; Huang V; Kolomeyer AM; Miller CG; Mishkin A; Maguire AM
Retin Cases Brief Rep; 2024 Mar; 18(2):164-167. PubMed ID: 36730596
[TBL] [Abstract][Full Text] [Related]
11. Successful oral treatment of Ganciclovir resistant cytomegalovirus with Maribavir in the context of primary immunodeficiency: First case report and review.
Bright PD; Gompels M; Donati M; Johnston S
J Clin Virol; 2017 Feb; 87():12-16. PubMed ID: 27987421
[No Abstract] [Full Text] [Related]
12. New Perspectives on Antimicrobial Agents: Maribavir.
Halpern-Cohen V; Blumberg EA
Antimicrob Agents Chemother; 2022 Sep; 66(9):e0240521. PubMed ID: 35916518
[TBL] [Abstract][Full Text] [Related]
13. Maribavir: Mechanism of action, clinical, and translational science.
Sun K; Fournier M; Sundberg AK; Song IH
Clin Transl Sci; 2024 Jan; 17(1):e13696. PubMed ID: 38071422
[TBL] [Abstract][Full Text] [Related]
14. Clinical development of letermovir and maribavir: Overview of human cytomegalovirus drug resistance.
Piret J; Boivin G
Antiviral Res; 2019 Mar; 163():91-105. PubMed ID: 30690043
[TBL] [Abstract][Full Text] [Related]
15. Fast selection of maribavir resistant cytomegalovirus in a bone marrow transplant recipient.
Schubert A; Ehlert K; Schuler-Luettmann S; Gentner E; Mertens T; Michel D
BMC Infect Dis; 2013 Jul; 13():330. PubMed ID: 23870704
[TBL] [Abstract][Full Text] [Related]
16. Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection.
Chou S; Song K; Wu J; Bo T; Crumpacker C
J Infect Dis; 2022 Sep; 226(4):576-584. PubMed ID: 32726419
[TBL] [Abstract][Full Text] [Related]
17. Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients.
Avery RK; Marty FM; Strasfeld L; Lee I; Arrieta A; Chou S; Tatarowicz W; Villano S
Transpl Infect Dis; 2010 Dec; 12(6):489-96. PubMed ID: 20682012
[TBL] [Abstract][Full Text] [Related]
18. Maribavir: First Approval.
Kang C
Drugs; 2022 Feb; 82(3):335-340. PubMed ID: 35147913
[TBL] [Abstract][Full Text] [Related]
19. Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing.
Chou S; Watters M; Sinha R; Kleiboeker S
Antiviral Res; 2021 Sep; 193():105139. PubMed ID: 34273445
[TBL] [Abstract][Full Text] [Related]
20. Cytomegalovirus related hospitalization costs among hematopoietic stem cell and solid organ transplant recipients treated with maribavir versus investigator-assigned therapy: A US-based study.
Schultz BG; Bullano M; Paratane D; Rajagopalan K
Transpl Infect Dis; 2024 Apr; 26(2):e14216. PubMed ID: 38221739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
